The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Year: 2010
Type: review
Source: Nature Reviews Drug Discovery
DOI: 10.1038/nrd3185
Institution: Bayer (Germany)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Pfizer, European Society of Cardiology
OpenAlex ID: W2153438515